Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Bluemtec Co's annualized net income for the quarter that ended in Jun. 2026 was ₩7,906 Mil. Bluemtec Co's average Total Stockholders Equity over the quarter that ended in Jun. 2026 was ₩48,113 Mil. Therefore, Bluemtec Co's annualized ROE % for the quarter that ended in Jun. 2026 was 16.43%.
The historical rank and industry rank for Bluemtec Co's ROE % or its related term are showing as below:
XKRX:439580'
s ROE % Range Over the Past 10 Years
Min: -10.38 Med: -10.05 Max: 9.2
Current: 9.2
During the past 6 years, Bluemtec Co's highest ROE % was 9.20%. The lowest was -10.38%. And the median was -10.05%.
XKRX:439580's ROE % is ranked better than 59.62% of 629
companies
in the Healthcare Providers & Services industry
Industry Median: 6.19
vs XKRX:439580: 9.20
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Jun. 2026) net income data. The Revenue data used here is four times the quarterly (Jun. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Bluemtec Co ROE % Related Terms
Bluemtec Co ROE % Historical Data
* Premium members only.
The historical data trend for Bluemtec Co's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Bluemtec Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bluemtec Co ROE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Bluemtec Co's ROE % distribution charts can be found below:
* The bar in red indicates where Bluemtec Co's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Bluemtec Co (XKRX:439580) has a ROE % of 16.43% as of Jun. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Bluemtec Co and its competitors. According to the industry distribution chart, Bluemtec Co ranks #254 out of 629 companies in the Healthcare Providers & Services industry, placing it in the top 40.4%.
Is Bluemtec Co's ROE % too high?
Bluemtec Co's current ROE % is 16.43%. The Healthcare Providers & Services industry median ROE % is 6.19. Bluemtec Co's value of 16.43% is 165.4% above this industry median. Based on the distribution chart, Bluemtec Co ranks #254 out of 629 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Bluemtec Co has a GF Score™ of 47/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bluemtec Co's ROE % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Bluemtec Co ranks #254 out of 629 companies for ROE %. This puts Bluemtec Co in the upper half of its industry. The industry median ROE % is 6.19. Bluemtec Co's value of 16.43% is 165.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Healthcare Providers & Services company?
The median ROE % among Healthcare Providers & Services companies is 6.19, based on 629 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bluemtec Co's current ROE % of 16.43% is 165.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Bluemtec Co and its competitors. For the Healthcare Providers & Services industry, the median ROE % is 6.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bluemtec Co's current ROE % is 16.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bluemtec Co stock overvalued right now?
Based on GuruFocus' analysis, Bluemtec Co (XKRX:439580) is currently considered Significantly Undervalued. The stock's GF Value™ is ₩6,820.65, compared to a current price of ₩1,996.00 — trading 70.7% below its estimated fair value. The current ROE % is 16.43% and 165.4% above the Healthcare Providers & Services industry median of 6.19. Bluemtec Co's overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Bluemtec Co (XKRX:439580), the current ROE % is 16.43% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bluemtec Co (XKRX:439580) Overvalued in 2026?
Based on GuruFocus' analysis, Bluemtec Co stock appears to be undervalued.
The current stock price of ₩1,996.00 is trading 70.7% below its estimated GF Value™ of ₩6,820.65.
GuruFocus considers Bluemtec Co to be Significantly Undervalued.
Key valuation signals for XKRX:439580:
ROE %: 16.43%
GF Value™: ₩6,820.65 vs. price of ₩1,996.00 (70.7% below fair value)
Industry Position: 165.4% above the Healthcare Providers & Services median (#254 of 629)
No single metric tells the full story. See the XKRX:439580 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bluemtec Co Ltd is a company whose main business is selling prescription drugs through an e-commerce platform. It operates two pharmaceutical distribution platforms, BluePharmKorea targeting hospitals and clinics, and KoolPharm targeting pharmacies and provide IT services to operate and advance these two platforms. In addition, it is operating BlueLabs, which provides services and website development for pharmaceutical companies and medical institutions.
47GF Score
Get the complete analysis for XKRX:439580
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:439580 has been successfully added to your 
